文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

伤寒疫苗加速联盟(TyVAC):疫苗效果研究设计:加速引入伤寒结合疫苗并降低全球肠道热负担——2016年10月26-27日英国牛津会议报告

The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26-27 October 2016, Oxford, UK.
PubMed 文献 · Vaccine · 2017-08-10

新一代Vi伤寒结合疫苗(TCV)已获批用于幼儿,WHO免疫战略咨询专家组(SAGE)将于2018年发布更新立场文件。

要点

  • 新一代Vi伤寒结合疫苗(TCV)已获批用于幼儿,预期保护较既往疫苗更持久。
  • 会议结论:在非洲和亚洲选定点对9月龄至15岁儿童采用个体或整群随机设计开展效果研究。

核心结论

  • 会议结论认为,国家层面决策最好由非洲和亚洲选定研究点对9月龄至15岁儿童接种疫苗的效果研究数据来提供信息。

研究设计与样本

  • 2016年10月26-27日在英国牛津召开会议,启动TCV效果研究规划,讨论伤寒流行病学证据与数据缺口、WHO与Gavi方法和数据要求、TCV效力数据、数学模型成本效果分析及TCV接种与效果研究设计。
  • 参与者被要求就已在开展基于人群伤寒监测的3个研究点的研究设计发表意见。

主要发现

  • 新一代Vi伤寒结合疫苗(TCV)已获批用于幼儿,预期提供比既往疫苗更持久的保护。
  • WHO免疫战略咨询专家组(SAGE)已召集工作组审查TCV证据,并将于2018年发布所有伤寒疫苗的更新WHO立场文件,为Gavi未来TCV疫苗投资策略提供信息。

关键数值与推荐

  • 会议结论:在非洲和亚洲选定研究点对9月龄至15岁儿童接种疫苗,采用个体或整群随机设计,设计受人群特征、传播动力学和统计学考虑影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Typhoid fever is estimated to cause between 11.9-26.9 million infections globally each year with 129,000-216,510 deaths. Access to improved water sources have reduced disease incidence in parts of the world but the use of efficacious vaccines is seen as an important public health tool for countries with a high disease burden. A new generation of Vi typhoid conjugate vaccines (TCVs), licensed for use in young children and expected to provide longer lasting protection than previous vaccines, are now available. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has convened a working group to review the evidence on TCVs and produce an updated WHO position paper for all typhoid vaccines in 2018 that will inform Gavi, the Vaccine Alliance's future vaccine investment strategies for TCVs. The Typhoid Vaccine Acceleration Consortium (TyVAC) has been formed through a $36.9 million funding program from the Bill & Melinda Gates Foundation to accelerate the introduction of TCVs into Gavi-eligible countries. In October 2016, a meeting was held to initiate planning of TCV effectiveness studies that will provide the data required by policy makers and stakeholders to support decisions on TCV use in countries with a high typhoid burden. Discussion topics included (1) the latest evidence and data gaps in typhoid epidemiology; (2) WHO and Gavi methods and data requirements; (3) data on TCV efficacy; (4) cost effectiveness analysis for TCVs from mathematical models; (5) TCV delivery and effectiveness study design. Specifically, participants were asked to comment on study design in 3 sites for which population-based typhoid surveillance is underway. The conclusion of the meeting was that country-level decision making would best be informed by the respective selected sites in Africa and Asia vaccinating children aged from 9-months to 15-years-old, employing either an individual or cluster randomized design with design influenced by population characteristics, transmission dynamics, and statistical considerations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Meiring JE, Gibani M. The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26-27 October 2016, Oxford, UK. Vaccine. 2017. PMID: 28802757. doi:10.1016/j.vaccine.2017.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。